MedAI Verdict
All comparisons

Ibex Medical Analytics vs Tempus Digital Pathology

Ibex Medical Analytics and Tempus Digital Pathology both compete in pathology, but answer different questions. Ibex Medical Analytics is our pick for deployed globally: Most-deployed AI pathology platform globally. Tempus Digital Pathology earns the Paige acquisition (Aug 2025) slot: Paige Predict 123-biomarker pan-cancer suite, now part of Tempus AI. The right choice depends on whether your priority is deployed globally or paige acquisition (aug 2025).

Category
Pathology
Tools compared
02
Reviewed
October 20, 2026
Editorial silo
/best-ai-pathology

The two contenders

Best deployed globally

AI pathology software for prostate, breast and gastric cancer. One US FDA 510(k) clearance, for prostate.

Pricing
No public price. Sold to laboratories and health systems on enterprise contracts.
Compliance
FDA 510(k)

Best after Paige acquisition (Aug 2025)

Digital pathology AI from Paige, now part of Tempus: Paige Prostate Detect (FDA De Novo, CE-IVDR) plus research-use suites.

Pricing
No public price on the Tempus pages.
Compliance
FDA De Novo (DEN200080) / FDA 510(k) (FullFocus viewer) / CE-IVDR

Side-by-side specifications

How Ibex Medical Analytics and Tempus Digital Pathology compare

Pricing, compliance, and integrations sourced from vendor documentation. Verified October 20, 2026.

SpecIbex Medical AnalyticsTempus Digital Pathology
PricingNo public price. Sold to laboratories and health systems on enterprise contracts.No public price on the Tempus pages.
Free tierNo / unverifiedNo / unverified
HIPAANo / unverifiedNo / unverified
SOC 2 Type IINo / unverifiedNo / unverified
EHR integrationsNot specifiedNot specified
Founded——
HQILUS
Best forBest deployed globallyBest after Paige acquisition (Aug 2025)

Scroll horizontally to see both columns.

Editorial verdict

When to pick each one

When to pick Ibex Medical Analytics

Best deployed globally

Most-deployed AI pathology platform globally.

  • Israeli-origin
  • Prostate, breast, colon focus
  • Broad EU + US deployments
Read the full Ibex Medical Analytics review

When to pick Tempus Digital Pathology

Best after Paige acquisition (Aug 2025)

Paige Predict 123-biomarker pan-cancer suite, now part of Tempus AI.

  • NASDAQ:TEM
  • Most clinical-validation depth
  • FDA + CE-IVDR cleared modules
Read the full Tempus Digital Pathology review

Wider context

Open the full pathology comparison

Digital pathology workflows with FDA-cleared cancer detection (prostate, breast, colon), IHC scoring (HER2, Ki67), and AI-powered image management. Tempus, PathAI, Proscia dominate.

See all pathology

/best-ai-pathology